Sagimet Biosciences Inc. - 8-K Filing
Sagimet Biosciences reported Q1 2026 financial results with a net loss of $10.7 million (or -$0.33 per share) compared to $18.2 million in the same period last year, driven by reduced R&D expenses ($7.0M vs. $15.3M). The company secured $175 million in equity financing through an offering of 29.16 million shares at $6.00 per share and expects cash reserves to fund operations until 2028, including a planned Phase 3 trial for denifanstat in moderate-to-severe acne starting in H2 2026.
Tickers: $SGMT